Goleta, CA, United States of America

Chenyao Nie

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):

Title: **Chenyao Nie: Innovator in Antimicrobial Oligoelectrolytes**

Introduction

Chenyao Nie, based in Goleta, CA, is a prominent inventor with a keen focus on antimicrobial innovations. He has contributed significantly to the field of biochemistry with his groundbreaking patent that enhances the efficacy and safety of antimicrobial agents.

Latest Patents

Chenyao Nie holds a notable patent titled "Short conjugated oligoelectrolytes and uses thereof." This patent describes compositions and methods that provide specific antimicrobial activity against both Gram-positive and Gram-negative bacteria while exhibiting low toxicity towards mammalian cells. The core of this invention is a class of water-soluble molecules characterized by a hydrophobic interior and cationic side groups. The patent also emphasizes variations in the internal conjugated segment length and other molecular features that influence the antimicrobial efficacy and toxicity of the compositions.

Career Highlights

Working at the University of California, Chenyao Nie has integrated his research with practical applications in antimicrobial treatments. His work stands out for its innovative approach to addressing bacterial resistance, providing a valuable resource for the medical and pharmaceutical industries.

Collaborations

Chenyao Nie collaborates with esteemed colleagues such as Guillermo C. Bazan and Zichao Zhang, enhancing his research with diverse expertise. Their combined efforts foster advancements in the development of antimicrobial compounds, emphasizing safety and effectiveness in various applications.

Conclusion

Chenyao Nie's contributions to the field of antimicrobial research through his patented innovations represent significant advancements in combating bacterial infections. His work not only paves the way for future developments but also highlights the critical intersection of safety and efficacy in pharmaceutical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…